The stock of Celldex Therapeutics Inc. (NASDAQ:CLDX) decreased by -$0.15 on Friday to finish at $28.54, down -0.52 percent. The last five days have seen an average of 768,260 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$16.03. The average number of shares traded over the last 20 days was 468,915, while the average volume over the last 50 days totaled 460,232.
CLDX stock dropped -16.74% since last month. On 08/09/23, the company’s shares reached a one-month low of $27.52. The stock touched a high of $48.40 on 01/18/23, after rallying from a low of $27.01 in 52 weeks. The price of CLDX stock has declined by -35.97% or -$16.03 this year, reaching a new high 4 times. Still, the stock price is down -41.03% from the 52-week high.
Insider Transactions
CLDX stock investors should be aware that Celldex Therapeutics Inc. (CLDX) stock had its last reported insider trading activity 264 days ago on Dec 07. On Dec 07, EXECUTIVE VP & CSO KELER TIBOR sold 16,860 shares at $36.93 each. This transaction resulted in the insider making $622,611.
Valuation Metrics
Beta for the stock is 2.16. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 410.89, the price-to-book (PB) ratio of 4.86.
Financial Health
For the three months ended June 29, Celldex Therapeutics Inc.’s quick ratio was 16.90, while its current ratio was 16.90, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $117.59 million and revenue of $2.36 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CLDX’s return on assets (ROA) during the last 12 months has been -33.60%. There was a -35.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -36.10%.
Earnings Surprise
According to Celldex Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.27 million, while revenues rose by 40.74% to $0.97 million. It was predicted that Celldex Therapeutics Inc.’s quarterly earnings would be -$0.65, but it ended up being -$0.67, beating the consensus by 3.00%. EBITDA was -$33.61 million for the quarter. At the end of Celldex Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 21.77 million, while its total debt was $3.25 million. Equity owned by shareholders amounts to $47.26 million.
Technical Picture
Here’s a quick look at Celldex Therapeutics Inc.’s (CLDX) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 25.41%, suggesting the stock is oversold, with a 39.90% historical volatility rate.
The stochastic %K and %D were 20.39% and 23.33% respectively, while the average true range (ATR) was 1.26. Based on the 14-day stochastic reading of 18.15%, the RSI (14) reading is 28.96%. On the 9-day MACD Oscillator, the stock is at -0.94, and the 14-day reading is at -1.38.
Analyst Ratings
In its analyst report released on August 22, 2023, Wells Fargo began covering Celldex Therapeutics Inc. (NASDAQ: CLDX). The stock was rated as an Underweight by the brokerage firm. Analysts have assigned Celldex Therapeutics Inc. (CLDX) an Overweight rating. CLDX is a stock that is recommended for selling by 1 brokerage firm, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is CLDX’s price target for the next 12 months?
The current consensus forecast for the stock is between $21.00 and $73.00, with a median target price of $65.00. In analyzing these forecasts, the average price target given by analysts for Celldex Therapeutics Inc. (CLDX) is $59.57.
